FGF-9 Antibody (36923) [Alexa Fluor® 405]

• Reactivity: Hu
• Applications: WB
• Clone: 36923
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 405

FGF-9 Antibody (36923) [Alexa Fluor® 405] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human FGF-9
  Met1-Ser208
  Accession # P31371
• Specificity: Detects human FGF-9 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human (rh) FGF-3, -4, -5,
  -7, -10, -11, -13, -16, -17, -18, -19, rhFGF acidic, rhFGF basic, recombinant mouse (rm) FGF‑6, -8b, -8c, or -15 i
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from ascites

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FGF-9 Antibody (36923) [Alexa Fluor® 405]

• FGF9
• FGF-9
• fibroblast growth factor 9 (glia-activating factor)
• Fibroblast growth factor 9
• GAF
• glia-activating factor
• HBFG-9
• HBGF-9
• Heparin-binding growth factor 9
• MGC119914
• MGC119915
• SYNS3

Background

The FGF family is comprised of at least nine polypeptides that show a variety of biological activities toward cells of mesenchymal, neuronal and epithelial origin. All FGFs have two conserved cysteine residues and share 30‑50% sequence identity at the amino acid level. FGF-9, also named glia-activating factor, was originally identified and purified from the supernatant of a human glioma cell line as a heparin-binding mitogenic growth factor for glial cells. FGF-9 has also been shown to stimulate the proliferation of oligodendrocyte type 2 astrocyte progenitor cells, Balb/c3T3 fibroblasts and PC-12 cells. However, unlike FGF acidic and basic, FGF-9 is not a mitogen for human umbilical vein endothelial cells.

The human FGF-9 cDNA encodes a 208 amino acid residue protein that contains a potential N-linked glycosylation site. The native protein is glycosylated. FGF-9 exhibits approximately 30% sequence similarity to other members of the FGF family. Although FGF-9 lacks a typical secretion signal, the protein is secreted efficiently after synthesis. Rat FGF-9 cDNA has been cloned and shown to be highly homologous to human FGF-9. The two proteins differ only in one amino acid residue. The expression of the FGF-9 transcripts has been shown to be restricted to the brain and the kidney.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P31371()